My Written May 2013 CFSAC Testimony

CFSAC Meeting May 2013

Public Comment by Jeannette B., Attorney at Law

My name is Jeannette B. I have been sick with ME for more than seven years. I appreciate the opportunity to address the committee today.

I attended the FDA’s Drug Development Workshop in Bethesda, MD at the end of last month. If I had to use one word to describe that meeting it would probably be “surprise.”

Surprise at the fact that most of the few ME clinician experts were not invited to the meeting. Dr. Dan Peterson, arguably, THE most experienced and successful in treating ME patients, was not invited despite many patients’ desperate and repeated pleas to include him. Dr. Enlander—not invited. Dr. Kogelnik—not invited. Dr. Lapp—not invited. …

Ampligen, the only drug in advanced clinical trials for ME and the only ME drug on the horizon for years, probably decades—not on the agenda. A real head scratcher and another indication for what this meeting was not going to yield: tangible results or even just concrete next steps.

Going into the meeting knowing this, many patients who attended in person or via the live webcast were surprised at how well the meeting was organized and how respectfully patients were treated. I personally expected one and a half days of the same old ineffective and disingenuous we-feel-your-pain appeasement. There was definitely some of that; hard to switch gears after years of neglect and denial. Whether anything concrete will happen as a result of the meeting remains to be seen, but I got an ever-so-slight sense of something finally “clicking.” One thing I noticed, and it may or may not mean anything, after declaring ME a serious and life-threatening disease in September of last year, the term “life-threatening” was not used once during the April meeting. One can only hope that this is not backpedaling on the agency’s part.

The biggest surprise of them all though was the palpable eye-opening that occurred among the FDA officials. There were some genuine epiphany moments being had by the officials while hearing from patients. It was astonishing to hear so many of them express that they had been unaware of the extent of the patients’ suffering and symptoms. One has to ask what that says about the effectiveness of this committee, CFSAC, and the self-proclaimed advocacy group for this illness, the CFIDS Association of America. How is it possible that the FDA just now started to understand what patients and their doctors have been telling them for decades? One thing is for sure though: There is definitely no more deniability on the part of the agency and that alone is a big step forward.

However, as an Ampligen patient with amazing results on the drug, it was quite bittersweet to hear the clinical team leader of the FDA division responsible for not approving Ampligen in February of this year, Dr. Theresa Michele, admit, and stress, that, despite listening to many CFSAC meetings, she had not previously been aware of the symptoms of ME as clearly as she was as a result of listening to patients’ testimony at the April meeting. I cannot help but wonder if the decision not to approve Ampligen might have differed had there been a clearer understanding of the seriousness of the disease by the FDA before the decision was made. Given that Ampligen is in grave danger of disappearing in light of the denied FDA approval and the resulting very real risk of the sponsor’s bankruptcy, a predicament the FDA is well aware of, it’s almost intolerable to think that thousands or maybe hundreds of thousands of patients could be helped by a safe and effective drug had there just been more understanding of the disease. Tragic.

Given the many Aha! moments on the part of the FDA at the April meeting, it became undeniably obvious that it is crucial and exceedingly urgent that the FDA and other government agencies meet with the ME expert clinicians who have successfully been treating ME patients. Otherwise, it is fair to ask what the government is afraid of and whether it is really interested in making progress with regard to treatment options. It is also imperative that the government agencies finally acknowledge that there are many biomarkers for ME—biomarkers that are well established for other diseases—especially given the difficulty of getting drugs approved in their absence. I cannot tell you how frustrating it is to keep hearing that there are no biomarkers. Talk to Dr. Peterson, Dr. Klimas, Dr. Enlander and all the other experienced ME clinicians. They will gladly tell you about low NK cell function and other various immune abnormalities, like elevated cytokines; high viral titers; abnormal VO2 max and tilt table tests, etc. It’s long past due that the government learns about and tells insurance companies and pharma about them. Hearing from the FDA at the April meeting that the official establishment of biomarkers for ME will take at least a year is really unacceptable. Some of us don’t have another year to wait for something that has been available for a very long time. 30 years were wasted. Wouldn’t it be appropriate to try and make up for some of that time, finally?

The FDA meeting was a huge step in the right direction and I would like to take the opportunity to express my sincere thanks to Rear admiral Kweder and her team for an impressive and much appreciated meeting. Now, we just need some concrete results and some real progress.

Thank you!

Posted in Uncategorized | Tagged , , , , , , , , , , , , , , , | 7 Comments

Public Comment at FDA Stakeholder Meeting, April 25, 2013

My name is Jeannette B. I am paying for my own expenses for being here for this meeting.

I am here to urge the FDA to play a more proactive role in working with Hemispherx towards the accelerated approval of Ampligen. Quite obviously, a sub-group of ME patients has been identified as a result of their being  Ampligen responders and a tremendous amount can be learned from that. Yet, one gets the impression that the agency is not all that interested in the drug. Ampligen is not even a topic at this drug development workshop. Dr. Peterson, the physician with the most experience and success in administering the drug (and many other treatments as well), has not even been invited to be on one of tomorrow’s panels. One has to wonder if the FDA does not really want to learn from his vast knowledge and experience.

At the Ampligen FDA Advisory Committee meeting, the FDA stated that there is no path for Ampligen’s approval under any fast-track program. No explanation was given. In contrast, the FDA has recently developed new guidelines for an accelerated-approval process for Alzheimer’s drugs for patients who are not even sick yet! Why the drastically different standard, I wonder?

Looking back at the approval of AZT as the first drug to treat HIV and AIDS, it becomes clear that the FDA does indeed have discretion to adopt loser rules if the circumstances warrant it. At the end of last year, the FDA approved—under an accelerated approval program—Sirturo, a drug to treat tuberculosis that is five times more likely to kill patients than the standard drug treatment for the disease without proof of increased efficacy.

I am not convinced that the FDA’s hands are indeed bound when it comes to an accelerated approval of Ampligen.  Instead, it seems that an unfortunate double standard applied by the FDA to ME and Ampligen compared to other diseases and drugs has Ampligen headed straight towards the cliff, as Hemispherx is running out of money and the drug is going away, potentially forever.

Posted in Uncategorized | Tagged , , , , , , , , | 6 Comments

SF Chronicle Article on the FDA’s Denial of Ampligen

We got an article about the FDA’s denial about Ampligen on the front page of the San Francisco Chronicle’s weekend edition. I wish Dr. Montaya had framed his thoughts only positively (works in a sub-group of patients) instead of also negatively (not sure it works), but good coverage nonetheless.

Thank you, Courtney Alexander Miller, for landing the story with the Chronicle.  Thank you Erin Allday for taking an interest in our suffering and writing about it! And thanks to Paul Chinn for being gentle in his picture-taking.

 

Posted in Uncategorized | Tagged , , , , , , , , , , , , | 5 Comments

Sign the Ampligen Petition!

Please sign this urgent Ampligen petition.

As many of you know, the FDA is about to make a decision on whether or not to approve Ampligen, the drug that has improved my quality of life dramatically with very little side effects.  Other patients have had similar experiences. The deadline for the decision is February 2, 2013, but since that is a Saturday, I expect the FDA to act sooner than that. Therefore, time is of the essence. The FDA advisory committee meeting on the issue held in December 2012 didn’t go very well. The bias of the FDA against the disease and the drug was blatant and poorly disguised.

Other patients, those who don’t have access to the drug in the absence of FDA approval, urgently need this effective treatment and I need to continue my treatment because I will relapse off the drug, potentially very quickly. If the FDA doesn’t approve the drug, it will most likely become unavailable to me and everybody who is currently receiving it as part of a self-pay trial. There are no other treatments for ME and if Ampligen doesn’t get approved, there won’t be any treatment for at least a decade because there is nothing else in the pipeline.

We need everybody’s support by signing the petition linked to above. It literally takes less than a minute to sign. Please use your full name because that carries a lot more weight than just using your first name or “Anonymous.” If you could also ask friends, family, neighbors, (former) colleagues to sign, that would be extremely helpful. Imagine the domino effect if everybody gets just 5 other people to sign.

Dr. Nancy Klimas, leading ME researcher and specialist, makes the argument for the approval of Ampligen very poignantly. Dr. Klimas makes the point that the only reason not to approve Ampligen is the FDA bias against the disease. She does so by stressing the efficacy of the drug in a sub-group of patients proven in several trials over more than two decades and then saying:

“Yet, that’s not enough evidence for the FDA advisory committee to approve because they would like to see a conclusive biomarker. As a physician, I could live with this decision if I had other effective therapies to treat my CFS/ME patients. But I do not. Moreover, it defies common logic in used in drug approval for other complex immune mediated diseases.

Take for example, MS: Its earliest approved treatments had opposite immune effects. One interferon increased immune activity and a second interferon quieted immune activity. In the studies that led to approval, MS drugs, like Ampligen, had about a 40 percent success rate.

Clinical research for these early MS drugs produced no biomarkers other than a patient’s successful response to therapy, such as the case of Ampligen. The biomarker the FDA relied on for approval of MS — seeing if the lesions in a patient’s brain decreased — had no correlation to the patient’s improvement.

Why would the FDA approve MS drugs before there were concrete biomarkers to determine success? The answer is simple. The advisory panel saw MS as a serious disease that required interventions ASAP, and were willing to accept that clinicians would better understand where to use the first drugs with more experience using them. Now there are seven approved drugs for MS that have significantly improved quality of life for patients. But they are not willing to use the same logic for Ampligen.”

Even though Science Daily doesn’t normally run op-ed pieces, they picked up Dr. Klimas’ comments as an adapted version because of the critical importance of the issue.

Posted in Uncategorized | Tagged , , , , , , , , , | 12 Comments

“I have a plane to catch”

I am still working through all the emotions triggered by the highly anticipated December 20, 2012 FDA Arthritis Advisory Committee meeting about the approval of Ampligen, an immune-modulatory drug that has been very successful in treating a sub-group of myalgic encephalomyelitis patients, a devastating disease that has no FDA-approved treatment.  The meeting was held at the FDA White Oak Campus in Silver Spring, just outside of Washington, D.C. The purpose of the meeting was to make a recommendation to the FDA regarding whether or not to approve Ampligen. The FDA’s decision is due by February 2, 2013.

Introductory Thoughts

Before I dive into giving my impression of the meeting, I should mention that it was often hard to know who on the panel was talking because the meeting room was large and the public was seated at a bit of a distance from the committee. It was also challenging to hear everything that was said at times, as the sound system wasn’t always working that well. Ironically, the members of Hemispherx’s team were frequently admonished for not stating their name before every comment even though they were standing at the podium and everybody could seem them very well. Not so for the members of the committee who were sitting at a u-shaped table (thus hard to make out), but they were not required to state their name before speaking. So, often the public had no idea who was speaking.

After the long and exhausting trip, several very short nights and finding out that a good friend of mine had passed away unexpectedly just hours before the meeting, I didn’t have it in me to take notes. So, this is all from memory, which has been refreshed several times by discussing the meeting with other attendees.

I went to the meting fully aware that the chances for a recommendation to approve Amplgien were maybe better than ever, but probably not particularly good. But I definitely felt like the drug and, thus, the ME community, had a chance here. Maybe the FDA was finally ready to stop the neglect of ME. At least that’s what the agency was claiming, right? After all, there are no FDA-approved treatments for ME and none are on the horizon for years, if not decades.

In light of this huge opportunity, if I wanted to be able to feel like I had done all I could to support the approval of Ampligen, I just had to travel from Incline Village to D.C. to give my three-minute testimony at the meeting in person together with about 30 other patients and their relatives, Kim McCleary of the CAA and Dr. Sidney Wolfe, physician and director of Public Citizen’s Health Research Group.

I have improved so much on Ampligen that I felt I could handle the trip from Incline Village. It wouldn’t be easy and it wasn’t, but when is it ever easy when you are flying United? All three flights I booked on United during the last 2 months were canceled! But consider this: A few months ago, I couldn’t even handle a one-hour flight to the Bay Area to see my family. Now, I was able to tolerate a 27-hour trip to D.C., a day-long meeting and a 12-hour return trip. I have come a long way. All due to Ampligen. And I know in my gut that I am not done improving since I am still relatively early in the treatment.

The Meeting

What I hadn’t accounted for in my attempt to predict the outcome of the meeting was that at least some (maybe many) of the 14 committee members would know close to nothing about either the disease or the drug. I realize that the committee members are probably not paid much for preparing for, and attending, the meeting.  These things are mainly a resume builder. But given the stakes for hundreds of thousands of patients plus their families, it boggles the mind that some of those panel members felt comfortable being involved in deciding the future of Ampligen.

Two cases in point: One panel member opined that cognitive-behavioral therapy should be an effective treatment for ME. I am not going to dignify that statement with a comment. Another panel member asked whether Ampligen is available to patients now. What?! I just about fell off my chair when I heard this. This one member (and who knows how many more) was completely unaware of the fact that the only way to get Ampligen right now is to be part of the open-label trial, which means paying for the expensive drug out of pocket and moving to one of the few Ampligen locations and either uprooting one’s family or leaving one’s family behind. The sacrifices patients are making to get access to Ampligen are enormous. How did these guys, who were clearly unqualified to be involved, get on the committee? And why would they want to be on the committee given the unfamiliarity with the disease and the drug? There were two votes right there that we lost. Well, we didn’t lose them. We never had a chance of getting them in the first place. One thing you can’t argue with is ignorance.

What I also hadn’t taken into account was the fact that not everybody on the panel would have a grasp of the magnitude of their responsibility in casting their vote. There was little understanding among many panel members of how immense the suffering is in the ME community, how great the need for hope is among patients, how truly pivotal this decision was and how devastating a “no” vote would be. Quite frankly, I believe that some of the panel members who voted “no” simply have no idea what they have done.

The Public Testimony

The public testimony of patients was truly moving. More than once did it bring me and others to tears. To hear the details of so much suffering, back to back, was emotionally challenging, but so important.

The public was separated from the committee by a literal red tape and was not allowed to go beyond that line. Only Kim McCleary of the CAA and Dr. Wolfe of Public Citizen’s Health Research Group were allowed to “cross over” that line. Robert Miller’s wife, Courtney, was expressly refused access to the cordoned off area when she tried to speak to committee members after the meeting had ended.

The three-minute time limit per person was strictly enforced. The microphone was turned off at the 3-minute mark. I understand the need to keep a meeting agenda on track. Nothing is more painful than to waste time at an already long meeting. But I would have sworn that the FDA was allowed to go beyond their allotted time slot to make their case against Ampligen. They were not even reminded of the fact that they had gone over. It became very clear who the top dog was at the meeting. It certainly wasn’t the patients.

One big surprise was the testimony of Sidney Wolfe, of Public Citizen’s Health Research Group. Dr. Wolfe was originally slated for an earlier slot during the public testimony, but he somehow managed to change the order of speakers and be the last one—for maximum impact. He read from prepared slides, which all quoted the FDA, trashing Ampligen. I kept wondering what his big “but” would be, as I was sure he was there in the interest of the patients. Naïve, I know. When his three minutes were up, there was no “but.” Dr. Wolfe strongly urged the committee not to recommend approving Ampligen. I was flabbergasted. Dr. Wolfe does not know Ampligen. He does not understand ME. But he clearly believes that he was chosen to protect patients who’ve gone through hell for years and have no other options or prospects for treatment from themselves. Simply astounding!

The Vote

When it came time to vote on the safety issue, Dr. Buckley, the Acting Chairperson of the AAC, pushed really hard to skip the discussion that was supposed to precede the vote on each question. This was obviously driven by time concerns, as the meeting was running behind schedule and it was getting close to dinner time and to the plane departure times for some committee members. But the patient advocate, Alaine Perry, who did an outstanding job in representing us and really came through for the patient community throughout the meeting, pushed back even harder saying that she felt uncomfortable to have a vote on this important issue without any discussion. I’d like to add that it would also seem highly inappropriate and unusual to skip the discussion, but maybe not so much to somebody who pretty much knew what the outcome of the vote would be—with or without discussion. Reluctantly, Dr. Buckley gave in. The discussion was being had. The vote was “no.”

In the end, the committee overwhelmingly voted to recommend to the FDA not to approve Ampligen by casting a vote on four questions. The vote was “no” on three out of the four questions (9 to 4 and 8 to 5 respectively, so not close). I will list the four questions that were being voted on as well as the names of all committee members at the end of this post. It was abundantly clear to everybody in the room that the whole meeting was just a formality. Members of the committee had their minds made up before they ever entered the meeting room that morning. I understand that there are rules for the FDA on these matters and that an advisory committee meeting is probably required. But seriously, how cruel to put patients through the agony of such arduous travel when the decision was made already!

One member of the committee, Dr. Robert Lahita, was not present for voting. No explanation was given for his absence. The audience was merely told that he had left the room. This seems most unusual for such an important vote, not that it would have changed the outcome even if he had voted “yes.” I presume an emergency was the reason for his leaving, as no other explanation would be acceptable. But what seemed equally as unacceptable was the lack of explanation of his absence.

Dr. Komaroff

There is much to say about the meeting, but one of several things that stood out were the distressing votes cast by one of the few ME community’s specialist physicians, Dr. Anthony Kamaroff of Harvard University. Dr. Komaroff voted “no” on all four questions, even on the one question that the majority of the committee voted “yes” on! Throughout the meeting, Dr. Komaroff was hostile and dismissive towards Hemispherx, the sponsor of Ampligen. Still, his vote came as a shock to patients many of whom had pegged him as being on our team. Makes sense, right?! Unlike some of the other committee members who obviously knew nothing about the illness, Dr. Komaroff is familiar with the disease, probably more through his research than through clinical work, but nevertheless. Why would somebody like him sell out the patients he is studying?

I am sure that Dr. Komaroff has rationalized his decision. The data isn’t there. The drug’s efficacy hasn’t been proven. The drug’s safety hasn’t been proven. Hemispherx is not trustworthy. The problem with that line of arguing is that the data is open to interpretation. And that is exactly how some, though not enough, other committee members voted “yes.” Also, if one enters into the equation the fact that there is no other approved treatment for ME patients as a result of a scandalous neglect and abuse of this patient group by medical and scientific professionals and the government as well as the fact that the suffering is seemingly never-ending, I find it simply impossible to comprehend how somebody who knows this disease and understands the great suffering would reject Ampligen, a drug that has been given to patients for 24 years with no fatality and no serious side effects that can be definitively traced back to Ampligen.

I understand physicians who decide that they are not comfortable with providing Ampligen to their patients. The drug’s mechanism is not totally understood. The administrative burden that comes with prescribing it, as part of Hemispherx’s open-label trial, is a nightmare. The guidelines for shipping and storing the drug have to be meticulously followed. Infusion reactions do happen, including infiltrations, which are painful and potentially dangerous, although—based on patient reports—maybe less so than originally thought. Not wanting to get involved with Ampligen, even as an “ME doctor,” is a reasonable decision. But why torpedo the drug by keeping it out of the hands of those who are willing to help those who are suffering and therefore keeping it from patients altogether?

If “our” specialists do not help us, we are doomed. If I had to take a guess, I would bet that Dr. Komaroff didn’t bother to pick up the phone and call those physicians who, unlike him, actually know the drug: first and foremost Dr. Peterson, but also Dr. Bateman, Dr. Lapp, Dr. Klimas, Dr. Enlander. I would also bet that he never talked to a patient about his or her experience with Ampligen. Wouldn’t want to risk having to revise one’s opinion once made up. The dangers of the academic ivory tower!

After the meeting was over, Dr. Komaroff was chatting with Dr. Wolfe; two kindred souls who were clearly pleased with themselves. Dr. Komaroff had a huge smile on his face until I started taking pictures of him. It might have occurred to him that that was a bit inappropriate, as patients were crying and utterly devastated. Better not to provide any lasting evidence of such insensitivity to the patients.

Patient advocate, Anita Patton, approached Dr. Komaroff to remind him of his Hippocratic Oath and to let him know that he had done some real harm to patients with his vote. Dr. Komaroff’s response was, “I have a plane to catch.” He then moved away from Ms. Patton who, as a member of the public, wasn’t allowed behind the red tape and he proceeded to chat with somebody else in the area off-limits for patients.

Blowing off Ms. Patton that way was so undignified and he was, by his own admission, more concerned about catching his plane than the consequences of his actions. So, I couldn’t stop my self from saying, “I hope you’ll miss your flight.” I regret saying that. That wasn’t professional of me. And it was pointless, as I am sure Dr. Komaroff slept very well that night.

Dr. Unger

Dr. Unger of the CDC voted “no” on three out of the four questions. Mindy Kitei summed up very well, in her piece, “The Oxford Definition, It’s Baaack,” how many patients feel about that. Mindy said, “In my view, Beth Unger—who should know the suffering that millions experience with ME better than most FDA committee members—would vote for Ampligen approval when pigs fly.” I have nothing to add.

Dr. Marshall

I haven’t always gotten a good vibe from Dr. Gailen Marshall at the CFSAC meetings. For example, his reaction at the last CFSAC meeting after a patient testified about the consideration of suicide seemed totally inadequate and inappropriate. To suggest, as he did, that only patients who are not informed about all the exciting research being conducted (yeah, right!) would commit suicide was so off the mark. It can be more depressing to know about the research projects underway right now (not many!) than to be blissfully unaware of how neglected this illness still is and how small the chances are that there will be a treatment in one’s lifetime. But I must say that Dr. Marshall was as true champion for the ME community at the AAC meeting. He voted “yes” on all four questions. I wanted to give him a really big hug after the meeting. That’s how grateful I felt to him and still do. But I wasn’t going to risk getting arrested for breaking through the red tape.

The FDA

The FDA presentation consisted of a complete destruction of Ampligen. In all fairness, Hemispherx didn’t have all their ducks in a row and that was very unfortunate, but we have no other approved treatment, no prospect of one in the foreseeable future and no hope whatsoever. That didn’t seem to enter the equation for the FDA at all. Nor did the fact that Hemishpherx is a small drug company and, unlike the big pharma hitters, doesn’t have unlimited financial resources to conduct another 300 patient placebo-controlled, double-blind, randomized study, as the FDA wants them to do.

The FDA struggled hugely to distinguish side effects of the drug from typical symptoms of the disease. Seriously, abdominal pain? Show me an ME patient who doesn’t have that symptom as a result of having ME! And infections? Infections are one of the hallmark features of ME. Flu-like symptoms, headaches, fevers, pain, chills, diarrhea, depression, suicides, suicide attempts: all part of everyday living of an ME patient not on Ampligen.

Like a physician friend of mine pointed out to me: Could it be that there was a patient on Ampligen who had deep vein thrombosis because ME patients just can’t move much because they are too ill? And counting an incident of cancer as a side effect of the drug despite the fact that the cancer had been a pre-existing condition prior to starting Ampligen treatment, as had been determined after the cancer was detected, really makes you wonder.

Interestingly, the FDA didn’t consider the data of the ongoing open-label trial in terms of efficacy, which would have been a slam dunk in favor of the drug, but they did hold the side effects experienced by patients in that trial against the drug. I call that cherry picking.

Hemispherx was denied the opportunity for a rebuttal on the side-effects issue by Dr. Buckley, the AAC acting chairperson.

Another point the FDA kept making was that they were not convinced that Ampligen provides sustained relief, i.e., is a cure. In that spirit, I think the FDA should consider pulling insulin off the market, as it requires ongoing injections to treat diabetes. How about blood pressure medications, thyroid medications, cholesterol medications, etc.?

The FDA has approved more dangerous drugs for conditions less serious than ME, a serious and life-threatening disease, more than once.

There is no doubt in my mind that Ampligen would have received a favorable recommendation had it been developed by big pharma or if it were a treatment for most other diseases, even those less serious that ME. It would have received such recommendation even if it had more serious side effects. There is a clear bias against ME and against Hemispherx, the drug maker. Maybe the bigger problem is the complete lack of understanding of how serious this disease is. Without that, the risk-benefit analysis is bound to be completely off.

I had a short conversation with Dr. Michele, Clinical Team leader of the FDA, after the meeting. Dr. Michele, whom I found very personable, said that the FDA has yet to vote on the application. In other words, not all is lost. The reality is that the agency does not usually, if ever, approve a drug that has been recommended for denial. That conversation just added insult to injury and I couldn’t resist remarking that my growing up in East Germany has not bestowed a high level of confidence in me that a government would do the right thing.

But I have to hand it to the FDA in one respect: They have become excellent at paying lip service. Several times during the meeting were we assured that the agency is aware of the seriousness of the disease. A “sincere” appreciation of the large number of patients taking an interest in the matter was expressed numerous times. There was obviously some good public-relations briefing before the meeting.

The FDA received about 750 written patient comments before the meeting and that seemed to have left an impression on the agency, which remarked that they hadn’t seen so many written comments and so many patients in attendance in a long time at a meeting. They are starting to get the idea that we are not going to let up. They are starting to feel the heat. It may too late for patients my age and older. But we will still fight for the generations that come after us.

The Timing

The timing of the meeting, right before the holiday weekend, was disastrous for patients in attendance. Here is one example: One patient from Reno flew from Washington, D.C., to San Francisco where her plane to Reno was delayed by 6 hours only to be canceled after that. (You guessed it: United). She was unable to book another flight until after the holidays despite trying all airlines servicing Reno from the Bay Area because, well, it’s the holidays! So after getting up at 4 am Eastern on Friday, she rented a car at the San Francisco airport and drove, though a heavy rain storm for 6 hours, all the way to Incline Village that night, arriving at 2 am Pacific on Saturday (25 hours after getting up the prior morning) to stay there with a friend to receive her Ampligen infusion—which she would have normally gotten on Thursday had the meeting not been scheduled on that infusion day—at Dr. Peterson’s office later that day. She then got stuck in Incline Village until Sunday afternoon because of a heavy snowstorm affecting Mt. Rose highway, the road between Incline Village and Reno. Her kids who were home from college and whom she doesn’t see that often had been waiting for her in Reno since Friday afternoon when she was scheduled to arrive at home.

Scheduling the meeting right before the holidays also meant that patients had to pay higher airfare, were mostly unable to upgrade their tickets using miles to have a less painful flight and will be less functional throughout the holidays, as they recover from their trip. I myself have been stuck in Incline Village because of the heavy snow. I had planned on going home on Saturday to be with my 2-year old daughter and my husband for Christmas. I will attempt to fly out on Monday now. In case it’s still snowing too much then, I have a back-up ticket for midday Tuesday, Christmas Day!

The Webcast

Many patients have complained that the live streaming of the meeting was basically not working. They lost connection as soon as they had logged on. Some said that the webcast problem forced them to continually reboot their computers in addition to having to keep signing back on to the meeting. Many patients were not able to follow the meeting because of these technical issues. Some set up Skype meetings with fellow patients who were successful in logging on, but missed a good part of the meeting because of the technical issues.

I found these reports extremely surprising. The building the meeting was held in seemed to be very new and the technology looked state of the art. There were lots of cameras built in the high the walls. There was also a camera set up in the back of the room specifically for the meeting with a live cameraman.

The degree of disability and/or resulting poverty of many patients made it impossible for them to attend in person. The sub-par quality of the webcast also prevented them from attending via the Internet.

It seems that this was no isolated incident and that the FDA is well aware of its technical issues. The meeting notice contained this disclaimer regarding the webcast: “While CDER is working to make webcasts available to the public for all advisory committee meetings held at the White Oak campus, there are instances where the webcast transmission is not successful; staff will work to re-establish the transmission as soon as possible.”

In the year 2012, I can think of no excuse not to provide a quality live streaming of an event that is expected to create a lot of interest in people who are too sick to attend in person.

The Committee

Here are the 14 members of the AAC:

Larry Borish, MD

Lenore Buckley, MD, MPH

Ralph B. D’Agostino, Sr., PhD

Jacqueline Gardner, MPH, PhD

Lisa Gualtieri, PhD, ScM

Sean Hennessy, PhamD, PhD

Anthony Komaroff, MD, MA

Robert Lahita, MD, PhD

Gailenn Marshall, Jr., MD, PhD

Alaine Perry, MPH

Matthew Rudorfer, MD

Irwin J. Russel, MD, PhD

Elizabeth Unger, PhD, MD

James H. Ware, PhD

The Four Questions

Here are the four questions the committee voted on:

1. Considering the totality of the data, is there substantial evidence of efficacy for Ampligen for the treatment of patients with chronic fatigue syndrome (CFS)?

Yes: 4 (Borish, Marshall, Perry, Rudorfer)

No: 9

Not Voting: 1

2. Has the safety of Ampligen been adequately assessed and characterized for the treatment of chronic fatigue syndrome (CFS)?

Yes: 4 (Marshall, Perry, Rudorfer, Perry)

No: 9

Not Voting: 1

3. Is the safety profile of Ampigen adequate for approval for the treatment of CFS?

Yes: 8 (Borish, Gardner, Hennessy, Marshall, Perry, Rudorfer, Russel, Unger)

No: 5

Not Voting: 1

I admit to being confused by the difference between question 3 and 4. I think, but don’t know for sure, that question #3 was a vote on whether the committee thinks that Hemispherx was being truthful when it provided the safety information regarding the two Ampligen trials.

4. Based on the information included in the briefing materials and presentations, has the applicant provided sufficient efficacy and safety data to support marketing of Ampligen for the treatment of chronic fatigue syndrome (CFS)?

Yes: 5 (Borish, Hennessy, Marshall, Perry, Rudorfer)

No: 8

Not Voting: 1

Posted in Uncategorized | Tagged , , , , , , , , , , , , , , , , , | 66 Comments

My Oral Testimony at the AAC Meeting Regarding Ampligen on December 20, 2012

My name is Jeannette.

I am very pleased to have this opportunity to address you and want to express my sincere thanks for your consideration of this critically important decision.

I have suffered with CFS for almost 7 years and was very fortunate to become a patient of Dr. Dan Peterson in Incline Village, Nevada and to begin Ampligen therapy 8 months ago.

Before I was stricken with this illness, I was a highly functioning international business attorney with a prominent international law firm working long hours and getting close to partnership.

That came to a screeching halt in 2006 when I became ill and unable function in my job and had to go out on disability.  Since then, I have incessantly endeavored to find treatments that would allow me to lead a somewhat normal life and to enjoy my family with my husband, Ed, and my 2-year-old daughter, Aimee with whom I lived in California—just one mile form Stanford University—all to no avail.

As a result, Ed and I decided that Ampligen was the only realistic hope we had. As you can imagine, this was an agonizing decision, as it necessitates—due to the lack of FDA approval—my living in Incline Village, 235 miles away from Ed and Aimee, except for weekend visits every few weeks.

Despite this heart-wrenching separation, I feel we have made the right decision, as I have recovered a significant part of my lost functioning to the point of more frequently being able to enjoy my time with my family.  Equally important, I can finally entertain hope for continued improvement rather than experience a steady deterioration of my condition. Ampligen has started to give Aimee her mother and Ed his wife back.

Despite the need to receive an infusion twice a week, I actually look forward to infusion days because I can feel the benefit of the drug. I implore you to consider my experience and that of many others who have benefitted tremendously from this drug and to give everybody in this long-suffering patient community hope for the future—for the first time.

There are no other drugs for CFS in the pipeline. If Ampligen doesn’t get approved, we are looking at years, maybe decades, of continued unspeakable suffering without any relief and without any hope. Not approving Ampligen would be devastating to hundreds of thousands of patients and their families.

Thank you!

Posted in Uncategorized | Tagged , , , , , , , , , , | 4 Comments

Llewellyn King: The Silent Suffering

Llewellyn King’s latest piece about ME, “Chronic Fatigue Syndrome: The Silent Suffering,” was published today in the Open Salon.  Mr. King, with his signature style of elegant and no-nonsense language, achieves what is so elusive for most writers: to give the reader a hint of what it’s like to live with ME. Here are the highlights:

“… of all the big diseases, [ME] is probably the least publicized, least talked about, and the most ignored in medical institutions…”

“As AIDS was initially, [ME] is haunted by fear, stigma and ignorance. It is misdiagnosed and often its victims are abused, thrown out of their families, and live in squalor and pain with little hope. They despair that they cannot convince doctors, their families or their loved ones that they are, in fact, sick.”

“… in that world of anguish, where the victims feel they are to blame because they are a burden to those who love them.”

“Most doctors are not qualified to offer [ME] diagnoses …”

“Suicide is common …”

“… an experimental drug, Ampligen, is helping a patient elite of about 750: They can get the drug in limited trials and can expect to pay between $25,000 and $40,000 a year for it.”

One clarification regarding the last quote: According to information published by Hemispherx, the maker of Ampligen, earlier this month, there are currently only 26 ME patients on Ampligen–no doubt due to the fact that the price tag puts this drug out of reach of most people.  I am one of the lucky few who may soon join the ranks of Ampligen recipients. 750 may be the total number of ME patients who have received Ampligen over the course of the last few decades, although I believed that number to be closer to 500, but I am not certain.

I feel the greatest gratitude towards Mr. King for his unwavering support.

Posted in Uncategorized | Tagged , , , , , , , , , , , | 9 Comments

What Might Cause ME? (Part 1) (From Get Well From ME)

For more of Giles Meehan’s brilliant videos about ME/CFS, please go to his website.

Posted in Uncategorized | Tagged , , , , , | Comments Off on What Might Cause ME? (Part 1) (From Get Well From ME)

“Guerilla Theater” Performance About Chronic Fatigue Syndrome

July 14, 2011 — For the first time, there is now a play that dramatizes the real-life stories of disabled Americans stricken with the little-understood illness called chronic fatigue syndrome (ME/CFS). This play can be performed in a “guerilla street theater” type of dramatic performance, open to the public and passers-by, or in an indoor setting, such as a community center or theater, perhaps as a fundraiser for organizations conducting research into the cause, treatment and cure for ME/CFS.

CFS, also known as myalgic encephalomyelitis or ME/CFS, is a disabling, sometimes fatal neuro-immune disease afflicting one million Americans and 17 million worldwide.

The script, titled I REPRESENT: INVISIBLE NO MORE, is a collection of true stories from people living with ME/CFS (chronic fatigue syndrome), and available to local community leaders and/or professional theater directors to use with community volunteers or professional actors.

Because the patients are either too sick to leave their homes or too sick to engage in public speaking ventures, the actors will represent them and share their poignant, sometimes funny narratives — hence the name of the play, I REPRESENT. The subtitle, INVISIBLE NO MORE, reflects the fact that the voices of homebound Americans will be heard for the first time in a theater performance

The public performances, when done as ‘street theater,’ where passers-by can stop and watch for as long as they want, offer the public a chance to hear what the lives of these disabled Americans are like.

“ME/CFS is a devastating disability. Many patients spend 5, 10, 20 years in or near bed, too weak to work, go to school or have a social life. Being homebound renders them invisible to the general public, allowing for little public awareness about the illness and many misconceptions. We hope to change that.” — Playwright Rivka Solomon, herself homebound/bedridden for much of the past 21 years.

In 2010, the National Institutes of Health allocated only $6 million to ME/CFS research. The motivation for this play is triggered by that lack of funding, along with a ground-breaking 2009 research paper published in Science, linking the illness to a newly-discovered HIV-like retrovirus, XMRV. The study was conducted by the Whittemore Peterson Institute, working with the National Cancer Institute and the Cleveland Clinic.

For decades, the cause of this illness (an illness that is “invisible,” like multiple sclerosis, lupus and early HIV retroviral infection) has remained elusive. Now finding a possible retroviral cause, XMRV, for ME/CFS is motivating patients to be more public.

ME/CFS first gained national attention around the same time as the AIDS epidemic, in the early 1980s. But as HIV/AIDS groups were able to organize, protest and demand respect, attention and funding, ME/CFS patients, too weak to function, crawled to bed.

Doctor Nancy Klimas, researcher and clinician at the University of Miami, recently stated in The New York Times that her ME/CFS patients are sicker than her HIV patients:

“My HIV patients for the most part are hale and hearty thanks to three decades of intense and excellent research and billions of dollars invested. Many of my CFS. patients, on the other hand, are terribly ill and unable to work or participate in the care of their families. I split my clinical time between the two illnesses, and I can tell you if I had to choose between the two illnesses (in 2009) I would rather have HIV.”

Although more than 4,000 peer-reviewed articles in medical journals have pointed to system-wide immune, neurological, endocrine, gastro-intestinal and cardiac abnormalities, a biologically-based diagnostic definition has eluded doctors. The result has been a catastrophic lack of care and ineffective (sometimes harmful) treatments. The disease occurs in people of all ages, from children to seniors, and also has occurred in cluster outbreaks from Nevada to New York.

CONTACT: Rivka Solomon
Rivka (at) ThatTakesOvaries (dot) org

Posted in Uncategorized | Tagged , , , , , | Comments Off on “Guerilla Theater” Performance About Chronic Fatigue Syndrome

Petition to Withdraw the PACE Study

Please sign the petition to withdraw the PACE study here. Below is the text of the petition:

“The PACE Study: ‘A Travesty of Science and a Tragedy for People with ME’

The published paper of the PACE trial study into ME is a ‘Travesty of Science and a Tragedy for people with ME.’

In light of the knowledge that the study has now been exposed as seriously flawed- in that it did not actually study people with ME -we the undersigned demand that the authors withdraw the paper with immediate effect.

In an unprecedented move the PACE trial was part funded by the Department of Work and Pensions. With final costs now reported to be between £4 and £5 million and a time scale of 8 years to complete it cannot be said to be a “value for money” exercise. The survey outcome has influenced the guidelines for ME produced by NICE (National Institute for Clinical Excellence), the ME services determined by BACME (British Association for CFS ME) and benefit support by the DWP (Department of Work and Pensions).

This petition will be presented to the Editor of the Lancet, the DWP, the MRC, the APPG for ME and as many MPs that we can identify who have an interest in ME.”

Posted in Uncategorized | Tagged , , , , , | Comments Off on Petition to Withdraw the PACE Study

MECFS Alert Episode 2

Here is the second episode of MECFS Alerts by our fried, Llewellyn King. This is one of the worst days I have had cognitively and I am barely able to form a thought and type this. So, I am just posting this with deep gratitude, but without any further comment.

Posted in Uncategorized | Tagged , , , , , , , | 3 Comments

Ampligen Treatment Study (AMP 511) starting in San Francisco Bay Area

We are a group of ME/CFS patients coordinating contact information for those interested in receiving Ampligen in the San Francisco Bay Area in California.

Sites administering the drug under the FDA approved open label AMP 511 study protocol have dwindled to Dr. Peterson in Incline Village, NV and Dr. Lapp in Charlotte, NC. An expansion of Ampligen sites has begun, including reactivation of Dr. Bateman’s site in Salt Lake City, UT.

A local physician that has experience administering the drug has contacted Dr. David Strayer at Hemispherx Biopharma, manufacturer of Ampligen, and has received the OK to start an open label Ampligen treatment protocol in the lower Peninsula Bay Area. The doctor needs a minimum of two participants for the study to be economically viable.

* The physician is a fee-for-service provider. Patients pay the doctor directly for services at the time services are rendered, and submit his/her own claims to insurance.

* Before being enrolled in the treatment protocol, patients will be tested for biomarkers to determine the likely response to Ampligen.

* After the doctor determines the patient is appropriate for the study, they must remit a $1,000 deposit to the physician, after which the paperwork will be started for the study. The paperwork takes approximately two months to complete and approve before Ampligen is administered.

* Patients withdrawing during the paperwork period will forfeit their $1,000. Patients who continue will have the deposit applied to their cost of Ampligen administration.

* The total cost of the administration of Ampligen to each participant is approximately $2,500/month.

* The physician estimates for many patients it’ll take 18 months to achieve the full therapeutic and stabilization effects of Ampligen. Participants should plan for that timeframe.

* Two Bay Area ME/CFS patients have already started the process to qualify to receive Ampligen under the open label treatment protocol.

Ampligen has a controversial history, including refusal of the FDA to approve retail marketing of the drug due to efficacy questions. Also, some patients state they’ve become worse on the drug. However, Ampligen has been clearly beneficial for a subset of ME/CFS patients. Some of the clinical factors that may identify these patients:

* Acute Viral Onset
* 2-5A Synthetase/RNase L Up Regulation
* Depressed Natural Killer Cell Cytotoxicity
* Persistent Herpes Virus Infections (EBV, HHV-6, CMV, etc)

Ampligen often initially causes dose dependent flu-like symptoms that can be significant. This has contributed to patient reports of Ampligen’s adverse effects. These are not the only health risks from Ampligen. Titrating the Ampligen dose may help minimize side effects. Ampligen is administered intravenously twice per week, so people with fragile veins may have difficulty with infusions. IV ports are sometimes installed.

Ampligen is administered under an experimental drug treatment protocol, and may be discontinued at any time without penalty by the participant, the FDA, the manufacturer, or the study principal investigator (usually the administering doctor). Before a person enrolls in the drug treatment protocol, the risks will be explained, and participants must sign a consent form. Persons that improve and consequently stop Ampligen for an extended period may eventually relapse after a unpredictable length of time. Some patients restart Ampligen when they start to relapse.

While many ME/CFS patients have an interest in Ampligen, the AMP 511 Cost-Recovery treatment protocol requirements are expensive:

*Ampligen is administered from 200mg or 400mg vials. The cost of the Ampligen alone, at the usual therapeutic dose of 400mg twice per week, is $1,200 per month, and is rarely covered by medical insurance. Some patients, however, may require a lesser dose.

*Infusion costs, administrative costs, and testing are extra, are generally not covered by insurance, and will cost approximately $1,300 a month.

This notice is for informational purposes, and is not intended to be an offer or guarantee of any sort.

Persons interested in Ampligen treatment in the San Francisco Bay Area, and have the resources to pay for the costs involved, please contact:samp511@comcast.net

Permission granted to repost

Posted in Uncategorized | Tagged , , , , , , , | 2 Comments

Llewellyn King Continues to Fight for Us: MECFS Alert Episode 1 (Parts 1 and 2)

Llewellyn King, a Washington columnist and executive producer and host of “White House Chronicle” on PBS, and his friend, Deborah Waroff, a New York writer and ME/CFS sufferer for 22 years, have started a new web-based TV show about Chronic Fatigue Syndrome, “MECFS Alert.”

Ms. Waroff said, “This is a terrible, debilitating and essentially lifelong disease which, like AIDS, suppresses the immune system. Our program has three objectives: to comfort the suffering; to change attitudes among physicians and medical institutions, and to implore the government to provide critically needed research funds.”

“In more than 50 years of reporting, I’ve never experienced so many people so misunderstood and abandoned by society and many doctors. I’ve worked on three continents and reported from around the world, but never have I had a response like the one I’ve had from writing about M.E./CFS,” Mr. King said.

Episode 1, Part 1

For the first show, Ms. Waroff and Mr. King interviewed Dr. Derek Enlander, ME/CFS specialist in New York. In part 1 of the first episode, they talked about Ampligen. Dr. Enlander said that he is about to start a trial of Ampligen, hopefully in July 2011, with patients being given infusions twice a week.  He said that, in his Ampligen trial 15 years ago, some patients did very well, other patients didn’t experience any improvement and a few patients experienced a worsening of their symptoms. According to Dr. Enlander, the likelihood for ME/CFS patients being helped by Ampligen is greater than 50%, but he admitted that he didn’t know how Ampligen works and why it is effective for some people and not for others. According to Dr. Enlander, Ampligen is so expensive because Hemispherix, the manufacturer of Ampligen, is a small company that doesn’t have the millions of dollars required for the FDA testing.

When asked by Mr. King what he would request from the US government, particularly the NIH and the CDC, Dr. Enlander said that he would like to see the government provide money for ME/CFS research, which “they have been reticent to do up until now.”

Episode 1, Part 2

At the beginning of part 2 of episode 1, Mr. King pointed out that it struck him that, unlike for other diseases, there is no lobby for ME/CFS patients and, besides Laura Hillenbrand, no celebrity standing up for the patient community like Elizabeth Taylor did, e.g., for HIV and AIDS patients. Dr. Enlander explained that ME/CFS is debilitating and that patients typically use up their savings in the very early stages of the illness because they cannot work, so they have no money left to donate for advocacy. He also pointed out that “the disease is so misunderstood that the lobby against the disease is pervasive.” Mr. King was wondering out loud why so many physicians are hostile,”brush[ing] it away,” making it psychiatric and refusing to take it seriously.  He called it “extraordinary.” Dr. Enlander had a short and sweet answer: “It’s called arrogance.” He likened it to the early MS days (20 or 30 years ago) when patients were told that they were hysterical because of the twitches that come with the illness. It was very heartening to hear a physician calling it like it is and not making excuses for his colleagues.

Then, Dr. Enlander talked a bit about his treatment protocol other than Ampligen. He started out by saying that he believes that ME/CFS is an immune system dysfunction and his protocol is aimed at acting on the immune system. The protocol is based on Kutapressin, a prescription injection, which was used in ME/CFS about 20 years ago. It was originally used in the 1950s in cases of Herpes zoster virus (shingles). Because some of the viruses implicated in ME/CFS are Herpes viruses, Kutapressin came to be used as a treatment for ME/CFS. But because only a small percentage of ME/CFS patients improved on Kutapressin, it was abandoned as a treatment option by other doctors in favor of looking for other treatments. Since there weren’t really any other treatment options out there, Dr. Enlander, however, decided to attempt complexing Kutapressin with a few other injectables. He mentioned vitamin B12, magnesium sulfate and folic acid. After refining the Kutapressin complex over the last 15 years, Dr. Enlander said he has increased its efficacy to about 65%. In patients with an HHV-6 titer of 640 or above, Dr. Enlander uses Valcyte in addition to the Kutapressin complex. He said that when the titer is lower than 640, the use of Valcyte is not warranted given its toxic qualities. Dr. Enlander said that the has talked to Dr. Montoya at Stanford about his Valcyte protocol.

Mr. King asked Dr. Enlander about clusters. Dr. Enlander does not think that ME/CFS is an infectious disease because otherwise it would be more prevalent in his opinion. Instead, Dr. Enlander’s and Dr. Jonathan Kerr’s theory is that the disease is genetic. They co-wrote a paper together on an abnormal genome, which Dr. Enlander says makes the disease potentially more prevalent. Since the viruses implicated in ME/CFS are so common and yet not everybody exposed to them will end up suffering from ME/CFS, their theory is that one has to have some genetic predisposition to have an abnormal reaction of the immune system. Their guess is that there is a “gene [that is] affecting an abnormal transponder in the methylation cycle.” Because of that, Dr. Enlander said, people shouldn’t be worried about contagion. He also said that looking at the methylation cycle is another possibility.

Dr. Enlander and Dr. Kenny de Meirleir also have patients who are on GcMAF right now.

At the end of the interview, Mr. King asked Dr. Enlander to say something hopeful to the suffering patient community. Dr. Enlander’s answer seemed to be a direct response to the PACE trial, although he didn’t actually mention it by name. He looked directly into the camera when he spoke: “This is a physical disease. This is not imagined. This is not a psychiatric disease. Changing actually ones outlook in life is not going to make a patient better. One cannot actually produce increased exercise and overcome this disease. In fact, in some cases, this might actually produce relapse. Exercise is good, over-exercise is bad. So, graded-exercise therapy, GET, is not the answer to this disease, neither is cognitive-behavioral therapy.”

Prompted by a question of Ms. Waroff, Dr. Enlander said that catching and treating the disease in the early phases might allow for some of the immune system reactions to be reversed.

There is a lot of excitement in the ME/CFS community about this new program. Patients are so grateful to feel that—finally—somebody really cares about them and is trying to help them.

Posted in Uncategorized | Tagged , , , , , , , , , , , , , , , , , | Comments Off on Llewellyn King Continues to Fight for Us: MECFS Alert Episode 1 (Parts 1 and 2)

Successful ME/CFS Demonstration at HHS San Francisco

Rivka Solomon who had organized a demonstration of patients with ME/CFS at the U.S. Department of Health and Human Services (HHS) in Washington D.C. on May 10, 2011 was, together with Bobbi Ausubel, also the organizer of the equally successful demonstration of  ME/CFS patients and their family and friends at the HHS regional office in San Francisco on May 25, 2011 .

I want to express my deepest gratitude to Rivka and Bobbi as well as to Susi and Andy, the two ME/CFS patients who attended the San Francisco rally and represented all those patients who were too sick to do so, for giving the ME/CFS community a voice. I know Rivka, Bobbi, Susi and Andy, no doubt, paid (or are still paying) for overextending to make the demonstration happen. A big thanks also goes to their friends and family who showed their support by attending that day and by helping Susan and Andy getting to the location.

Here is Rivka’s report on the San Francisco demonstration as well as notes from Bobbi and Rivka:

ME/CFS Demo in San Francisco, CA, USA

at the Dept of Health and Human Services

May 25, 2011

Contact: Rivka (at) ThatTakesOvaries (dot) org

Video of demo:

PRENOTE: A second small yet successful demonstration for the rights of people with ME/CFS was just held. A key goal of these mini-demos is to inspire more of the same; we hope you (those who are able) will hold a mini-demo, too. Only 1-5 people are needed to pull one off, get some press attention and make some waves. Make your own signs, or we can send you our pre-made 25-foot banner. All 3 goals of this Mini-Demo Strategy are found below.

WHO CAME:  On May 25, 2011, an ME/CFS public demonstration was held in front of the U.S. Department of Health and Human Services (HHS) Region 9 headquarters, in San Francisco, California. Despite the rain, eleven people came: two people with ME/CFS, Susan Kreutzer and Andy Au; three family members (mother, mother-in-law, spouse), including the protest co-organizer, Bobbi Ausubel; and six able-bodied friends. The multicultural group included people of Asian, Latino and Caucacasin decent, gay and straight, young adult and seniors. The people with ME/CFS came in spite of all the obstacles and barriers this illness throws in their way.

SETTING UP:  At 1:30 pm, the protesters positioned themselves on the busy, highly trafficked sidewalk in front of HHS Region 9, also known as the Federal Building. They unfurled a 25-foot banner that read: “Obama, Sebelius, HHS: Shame on you for abandoning 1 million sick and disabled Americans with ME/CFS and XMRV (Chronic Fatigue Syndrome and a newly discovered retrovirus). Clinical trials now!” (This banner was first used on May 10th at HHS national headquarters in Washington DC).

SECURITY:  Security came out immediately in the form of one person. He appeared to be the Head of Security of for the Federal Building/HHS. Bobbi told him what they were doing and how she had been told by the city police that they could be on the sidewalk without a permit, as long as they didn’t have a loudspeaker. The security officer agreed, took some of the demonstrators’ literature and went back inside. It was all very relaxed.

PRESS:  The protest co-organizers, Bobbi and Rivka, a mother/daughter team, had spent the days prior reaching out to the press. Success! The New York Times reporter who has covered ME/CFS in the past came “to say hi” (no article expected, but good to keep relations going) and a San Francisco Chronicle reporter and cameraperson came as well. The resulting article is found here.   Though this article was disappointing in the usual ways, its publication was still good news, as the SF Chronicle is one of the largest papers in the region. Plus, the reporter said she hoped to do an additional story on kids with ME/CFS. And to our knowledge, this is the first time an ME/CFS protest has made news in the U.S.

ACTIONS:  Standing in front of HHS with the banner for 1 hour, the protesters videotaped prepared and spontaneous statements (see resulting video), handed out flyers to passers-by and in a surprise action sang the song, “Clinical trials now!”

Also seen in this 2010 video:

HHS MEETING:  Also surprising, after the demonstration, there was a group meeting for a half hour with Eric Alborg, Regional Outreach Specialist of HHS’s Region 9. His boss, who was out of the country, is Herb Schultz, the Regional Director of Region 9. In the hierarchy, Alborg is positioned directly under Schutlz. (Alborg’s job main is to implement the new health care program.) Alborg had thought he’d be meeting with just one person, Bobbi, and had not known about the demo in advance. But after checking with someone (we don’t know who), he agreeded to meet with the whole group, that is, the two protesters who have ME/CFS and their three family members. Alborg was open to listening and wanted to know why the protesters were there. People talked about the concerns and needs of people with ME/CFS (funding and clinical trials!). The demonstrators put the struggle regarding ME/CFS in the context of HIV/AIDS, linking the possible retrovirus connection (XMRV). This discussion made sense since HIV is historically a key issue in San Francisco, due to a large and politically active gay community. The protesters emphasized to Alborg that HHS should have an understanding of the politics of all this, due to HIV/AIDS. They also told him that the information about this demo, and the meeting with him, would not be limited to the small group he was presently gathered with, but would be rapidly disseminated all around the globe via the internet, and that ME/CFS was an issue that was not going to go away.

Alborg’s suggestion to the protesters: 1) Call/lobby local institutions and legislators; 2) build coalitions with groups with other disabilities and chronic illnesses — groups that have already-established power and influence. (Though he did not say it, one protester went away thinking HIV/AIDS and Autism groups).

Bobbi gave Alborg copies of a letter she had written with her own personal statement on top, followed by a list of basic needs/demands from our ME/CFS community. Bobbi’s letters were addressed to HHS Secretary Sebelius, NIH Director Collins, NIAID Director Fauci and Schultz (Head of HHS Region 9). Alborg promised to make sure the letters were given to each.

OUTCOME:  Protesters reported leaving the demonstration and HHS meeting feeling great; like they had done something important, both personally and politically.

* * *

Note from Bobbi, demonstration co-organizer

== Personal statement, given to HHS officials ==

I am the mother of a daughter with the illness Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, or ME/CFS, which has very severely limited my daughter’s ability to lead a simple work and social life for over 20 harsh years. I have been her primary support. Much of the time she has been so sick she is often homebound or bedridden with disabling symptoms, not just “fatigue”!  Our family’s life activities and resources are centered around the health needs of this daughter (and sister) we love. We expect more support from our government by way of research and clinical trials for this disabling disease that affects more than a million Americans. Most people with ME/CFS are too ill to be standing outside HHS today for a demonstration.  Those of us gathered here are speaking for all who are ill, and we demand to have more research and clinical trials now.

BAusubel (at) yahoo (dot) com

* * *

Note from Rivka, demonstration co-organizer

== The Goals of Our Mini-Demo Strategy ==

It is my hope that ME/CFS patients will rise up and hold a number of these small mini-demos around the country, at HHS and CDC regional offices, of which there are 20. Demonstrators can use our banner, which we’d ship to them, or they can make their own signs. The 3-part goal of this strategy is to:

1. Get on HHS’s radar (get ME/CFS and XMRV patients on HHS’s radar).

2. Get press attention (get the patients’ perspective in the press).

3. Get the ME/CFS community used to images of people with ME/CFS demonstrating and protesting. Once they are accustomed to these images they won’t be as timid or trepidations about going out and doing it themselves (the ones who are able, of course).

Rivka (at) ThatTakesOvaries (dot) org

Posted in Uncategorized | Tagged , , , , , , | Comments Off on Successful ME/CFS Demonstration at HHS San Francisco

Summary of the 2011 Invest in ME Conference in London by Mike Turris

Mike Turris took some great notes at the Invest in ME conference that took place in London on May 20, 2011 . He was very careful not to disclose any of the information that is not supposed to be shared yet in order to avoid jeopardizing the future publication of new research findings:

“I cannot understand how nobody has posted a single word about the Invest in M.E. conference. I’m neither a writer nor a journalist nor have I got a medical degree, but I was there, and I saw and heard things that I think should be shared.

Exactly at nine o’clock, Annette Whittemore gave the first speech. I like this woman and I pray to God she will lead the WPI for many, many years. Dr. David Bell was the following speaker. I would like to emphasize the following ideas: Initial severity marks the rest of the illness / Children with CFS don’t recover, though sometimes in their twenties they may feel or do a bit better, but they will remain ill for all their lives / “I’m doing well”: people with CFS have a false perception of health and tend to say they are doing well in comparison with when they were terribly ill, but that does not mean that they are doing well in comparison with healthy people / Some people talk of recovery when they should talk of adaptation.

Dr. Andreas Kogelnik, a young MD, one of those guys who believes he has an answer to everything and has the world in his hands. He told us that some years ago he had been working with Dr. Montoya but is now the Founding Director of the Open Medicine Institute. He believes that with translational informatics and high technology, he will advance in the detection and implementation of clinical trials for CFS patients across a network of sites. He has his faith in the OMI Network. I send him my best wishes. Continue reading →

Posted in Uncategorized | Tagged , , , , , , , , , , , , , , , , | 2 Comments

Tips on Talking to Family and Close Friends by Toni Bernhard

Toni Bernhard, author of How to Be Sick: A Buddhist-Inspired Guide for the Chronically Ill and Their Caregivers, wrote a very insightful piece, “When chronic illness strikes: Tips on talking to family and close friends,” about how to try and gain acceptance and support from your family and friends. Many ME/CFS sufferers, including myself, really struggle with that aspect of the illness, as if the physical challenges weren’t bad enough. Toni’s fourth suggestion particularly resonated with me—not because I have been good at accepting that I might not get from others what I need, but because I think it is an area of growth that I would do well focusing on:

“4. In the end…accept their limitations. Some family and close friends may never accept this change in your life. Try to recognize that this inability to accept you as you are now is about them, not you. Your medical condition may trigger their own fears about illness and mortality. You can’t always fix how others think of you or treat you, but you can protect yourself from allowing their lack of understanding to exacerbate your symptoms. The best way to protect yourself is to cultivate compassion for them. If you can learn to wish them well despite their inability to support you, you can free yourself from the mental suffering that arises from your desire for them to be different than they are. The physical suffering that accompanies chronic illness is difficult enough without adding mental suffering to it.”

Posted in Uncategorized | Tagged , , , , , , | 2 Comments

Dr. Teitelbaum Advertises Again on Huffington Post

Dr. Jacob Teitelbaum, MD and former ME/CFS patient, published another article on Huffington Post, XMRV Update and a Possible New Treatment for Chronic Fatigue, yesterday. This one was even more disappointing than his recent piece, which I commented on earlier this month.

First of all, the title speaks of “chronic fatigue.” The name of our illness in the US is “chronic fatigue syndrome” or “CFS.” While I can see that lay people would make an innocent mistake when referring to it as “chronic fatigue,” I can think of no excuse for doctors who claim to have expertise in the ME/CFS area doing the same. Is it really asking too much to say “chronic fatigue syndrome”? The belittling name, chronic fatigue syndrome (thank you, CDC!)—which is always good for a few yeah-I’ve-been-really-tired-recently-too comments—is bad enough. Having ME/CFS is so much more than being chronically fatigued. But calling ME/CFS “chronic fatigue” grossly minimizes the seriousness and multi-systemic nature of the disease even more than the official name already does—and that’s hard to do. Continue reading →

Posted in Uncategorized | Tagged , , , , , , , , | 4 Comments

Making the truce, a short note for ME Awareness day 2011 by Jane Winter

Today is ME/CFS Awareness Day.  “Making the truce, a short note for ME Awareness day 2011” by Jane Winter talks well about flare-ups: how they are not just hard for what they mean in the moment—even more restrictions than usual—but how they are frightening because they could be the beginning of the end.  And remember: it’s invisible.

Except:

“Here’s the thing though.  Every time, *every* time a flare up happens, even after six and a half years of being bounced up and down by ME, you think “Is it now? is this the time I won’t bounce back? is this the time I will get worse and worse, back to how I was at the beginning, or further, into the 25% of sufferers who are bedbound?” The thought is, every single time, terrifying.”

Posted in Uncategorized | Tagged , , , | Comments Off on Making the truce, a short note for ME Awareness day 2011 by Jane Winter

What To Do When Your Friend Has An Invisible Illness—ME/CFS? (From Get Well From ME)

More from Giles Meehan at Get Well From ME.  This time, Giles talks about “What To Do When Your Friend Has An Invisible Illness – ME/MECFS/CFS.” Here are some of Giles’ words that resonated with me the most:

“The worst thing is that … you have to face the prejudices of having one of the most misunderstood illnesses there is. … ME is an invisible illness. When you do actually feel well enough to go out for a little bit, and people see you, they might say that you look well. But they don’t know that that might be the only thing you can cope with that whole day, or that whole week. …

As if having ME isn’t bad enough, then feeling like you’re on trial all the time, having to justify to people who haven’t been where you are, that you really are so ill, when all you wish is that you weren’t, is just adding a massive insult to injury.”

Here is what Giles suggests friends of people with ME/CFS can do to help:

“… believe them. Acknowledge and accept that the illness is real – because it is. You don’t seriously think that someone with ME would choose a life like that, do you? … People with ME are usually the most conscientious and highly motivated people I’ve ever met. We honestly, desperately want to do stuff. It’s not like when your back is turned, we stop “pretending to be ill” and just get on with fun things and enjoy an easy life! No, it’s the complete opposite. When you see us, we are mustering all our energy to be as normal and energetic and look as healthy as we possibly can – and as soon as you’re gone, we collapse, feeling far worse than you could imagine! It’s so easy to really hurt someone who has ME by making little comments or acting in a way that shows that you don’t believe they’re really ill, or that you think they’re exaggerating how bad they feel.”

Posted in Uncategorized | Tagged , , , | Comments Off on What To Do When Your Friend Has An Invisible Illness—ME/CFS? (From Get Well From ME)

Teitelbaum’s Critique of PACE Fails to Deliver

In his March 9, 2011 article in Psychology Today, Dr. Jacob Teitelbaum took a look at the PACE trial done in the UK, which studied the effect of cognitive behavioral therapy (CBT) and graded exercise therapy (GET) on patients with ME/CFS. The hypothesis of the study was that ME/CFS is the result of fear-based avoidance of exercise. The idea was that CBT would eliminate the patients’ fear of exercise and GET would build up the patients’ stamina. Therefore, the premise of PACE was that ME/CFS is a psychological illness and it concluded that CBT and GET improve ME/CFS patients’ conditions and are, thus, valid treatments for ME/CFS. In truth, some patients improved somewhat. Some patients had no improvement, but even the patients who did were far from normal levels after the “treatment.”

The position that ME/CFS is a psychological illness has been proven wrong time and time again, so, when I read the title of Dr. Teitelbaum’s article, “PACE Study May As Well say Cancer Is All In Your Mind,” I was excited because it hit the nail right on the head: People with serious illnesses, such as cancer or ME/CFS, benefit from well-done therapy that helps them cope with their emotions about being ill.  Doh!  But my excitement only lasted until I read the sub-title, “Contrary to this report, CFS is a real illness.”  This, unfortunately, is a great example of what’s wrong with most media coverage on ME/CFS. To stay with the cancer analogy, Dr. Teitelbaum may as well have said “Contrary to this report, cancer is a real illness.” Of course it is!  No responsible and sane person would suggest otherwise. But what would be the reason for pointing that out then? Anybody? I can’t think of one either.

Back to ME/CFS: It has been proven many times, using biological markers, that ME/CFS is a “real” (i.e., physical) illness. So, why do we keep reading headlines suggesting that its legitimacy still is in question, such as “Is Chronic Fatigue Syndrome Real?” or, like here, “Contrary to this report, CFS is a real illness”? I can understand that the legitimacy of ME/CFS is questioned by parties interested in classifying it as psychological, such as disability insurance companies who only have to pay for two years for disabilities due to psychological illnesses as opposed to until the 65th birthday of the claimant for physical illnesses. But clearly, journalists should be reporting on this disease more objectively, but they often don’t—either because they are biased or because they are too lazy to really understand. If I understand Dr. Teitelbaum correctly, it was his frustration with this kind of media coverage of the PACE trial, which often suggests that ME/CFS is all in patients’ heads, that lead him to write his article. So, I believe that he was well-intentioned.

But here are the problems with Dr. Teitelbaum’s article:  In addition to having a completely misguided premise (see above), the PACE trial’s design was fatally flawed because its recruitment merely focused on fatigue and not on post-exertional malaise, which is the hallmark symptom for ME/CFS and the distinguishing factor from other illnesses causing fatigue (Not only does exercise not help ME/CFS patients, it usually makes them feel worse.).  Therefore, many or possibly even most people who were recruited for the study were people with fatigue due to depression and other non-ME/CFS conditions.  Yet, even though the title of his article suggests that he has an issue with PACE, Dr. Teitelbaum fails to address the problems of the PACE trial altogether. Instead, he treats PACE as if it was a scientific—or should I say “real”?—study. By doing so and by making  the “realness” an issue in his sub-title, Dr. Teitelbaum, ironically, is helping to perpetuate the very myth that he purports to fight: that ME/CFS is a psychological illness. (And by the way, people with psychological illnesses can surely not be thrilled to see him imply that their disease is not “real.”)

I also find it quite questionable that Dr. Teitelbaum still claims that he can cure ME/CFS patients with his S.H.I.N.E. protocol. Suggesting that a few hormones and nutritional supplements, etc., will allow ME/CFS patients to go “From Fatigued to Fantastic” (the title of his book—a slap in every ME/CFS patient’s face) is ludicrous. To be sure, I am a big fan of alternative treatments and supplements to support ME/CFS patients’ systems, but I doubt they will cure ME/CFS and claiming so helps to downplay the seriousness of the disease. And does “exercise as able” sound a bit like “graded exercise” to anybody else? However, Dr. Teitelbaum does use Dr. Montoya’s Valcyte protocol with some of his patients.

Posted in Uncategorized | Tagged , , , , , , , , | Comments Off on Teitelbaum’s Critique of PACE Fails to Deliver